top of page
cPass+brochure+front+page+image.jpeg

cPass

We are proud to offer cPass, the first rapid test for measuring neutralising antibodies against SARS-CoV-2, now added to the ARTG.

cPass delivers reliable data to help estimate individual immunity against SARS-CoV-2.

Take the first step towards integrating cPass™ into your laboratory or clinic’s practice by getting a quote today!

sVNT Kit.jpeg

cPass sVNT Kit now added to the ARTG

The first rapid smart test kit for measuring functional neutralising antibodies (NAbs) within an hour in most research or clinical labs.

The cPass™ SARS-CoV-2 Neutralising Antibody Detection Kit (or, SARS-CoV-2 sVNT Kit), offers a faster, simpler, and more scalable alternative to traditional neutralising antibody tests like VNT, pVNT, and PRNT. 

 

Measuring functional neutralising antibodies (NAbs) within an hour, unlike traditional tests that take days. Done without the need for live biological materials or strict biosafety containment like BSL3. 

Faster and Simpler

Measures functional neutralising antibodies (NAbs) within an hour, without the need for live biological materials or strict biosafety containment.

NAb Specific

cPass™ directly measures NAbs, distinguishing them from other binding antibodies that do not possess the neutralising function.

Safe and Accessible

A versatile tool for assessing immunity across diverse patient groups. No biohazard facility required, making cPass highly accessible to laboratory and clinical practises globally.

IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia

Scalable & Automatable

cPass™ Neutralization Antibody Detection Kit can be rapidly conducted within an hour in most labs, and is also amenable to high throughput and fully automated testing.

Doctor's Clinic

The new Gold Standard for Labs and Clinics Globally

Having been added to the Australian Register of Therapeutic Goods (ARTG), cPass™ is setting the new gold standard in neutralising antibody detection for labs and clinics across the world.

With unprecedented speed, sensitivity, and specificity, cPass™ is a game-changer in clinical practice, empowering healthcare professionals with actionable data to guide patient care and public health decisions.

Take the first step towards integrating cPass™ into your lab or clinic's practice by getting a quote today!

Businessman

Why measure levels of immunity to COVID-19?

By estimating immunity or measuring the real-world effectiveness of vaccination programs, we can better manage public health risks and guide the safety, protection and preparedness of our communities.

Individual Booster Requirements

Measuring neutralising antibody levels with cPass™ may determine how long immunity lasts and can help inform decision making about booster requirements.

Immuno-compromised
and elderly

In immuno-compromised individuals, an effective vaccination strategy together with cPass™ may offer an added level of assurance to those most vulnerable.

Risk Stratification

An understanding of infection and illness risk empowers effective decision making. cPass™ may help inform public health policy, business management and personal peace of mind.

International Travel

Concerns related to cross border spread of COVID-19 can possibly be minimised using cPass™. Travel decisions may be more confidently informed when venturing into areas with increased health and safety risks.

ImageForNews_700907_16414755230108163.jpg

Neutralising antibodies:
an important biomarker
of immunity.

Having been added to the ARTG, cPass™ is the world's first rapid test for neutralising antibodies (NAb) against the SARS-CoV-2 virus.

cPass™ directly measures NAb, a type of antibody produced by the immune system against SARS-CoV-2.

NAb directly block the SARS-CoV-2 virus from entering human cells, making them the most important biomarker of immunity.

Contact us to learn more about cPass™.

Get a Quote, and take the first step towards integrating cPass into your lab or clinic today.

Complete the quote form, and an IBH representative will be in touch.

IBH has distribution rights to commercialise, launch and supply cPass™ and cPass Express™ in Australia, New Zealand, South Pacific Islands, Bangladesh, Philippines and Indonesia.

If you'd like to find out more about cPass™, feel free to contact us.

cPasssVNT Kit Quote Request

Thanks you! We'll be in touch.

cPass Quote Request
bottom of page